Real-World Study Observing Ruscus Aculeatus L. Treatment Effects in Adults with Chronic Venous Disease Assessing Symptom Control, Quality of Life, Adherence, and Safety Over 90 Days

What this Trial Is About

Researchers are gathering real-world data to understand how Ruscus aculeatus L. works for adults with symptomatic chronic venous disease CVD classified as CEAP C1 to C6. This observational study focuses on evaluating the treatments effectiveness, safety, adherence, and impact on quality of life over 90 days. The study is conducted across multiple centers, following patients who receive Ruscus aculeatus L. as part of usual clinical care. Participants prescribed Ruscus aculeatus L. will be monitored for about 90 days without any additional study-required treatment or intervention. Treatment and care decisions are made by the patients doctors during routine visits. Clinical data including disease severity using the revised Venous Clinical Severity Score rVCSS, pain measured by the Visual Analog Scale VAS, quality of life assessed by the Chronic Venous Disease Quality of Life Questionnaire CIVIQ-20, adherence to treatment via the Visual Analog Scale for adherence VAS-U, and safety through adverse event reporting will be collected at baseline, Day 30, and Day 90. Participants will have routine clinic visits at these three time points where clinical assessments, questionnaires, and safety monitoring occur. Researchers aim to track changes in symptoms, pain, quality of life, and treatment adherence while observing any side effects. The total participation time spans approximately 90 days, allowing for comprehensive real-world observation of Ruscus aculeatus L. use in managing chronic venous disease.

Ruscus Evaluation for Symptom Control in Uncomplicated Chronic Venous Insufficiency